EC
Eliana Clark
EVP, Chief Technical Officer

Eliana Clark insider trades: Intellia Therapeutics (NTLA) stock sales

EVP, Chief Technical Officer, Intellia Therapeutics Last trade Mar 2, 2026 13 Form 4 filings
$96K
Sold, last 12 months
2 sales
$0
Bought, last 12 months
0 buys
11
Open-market trades
since 2023
1
Company
last trade 2026

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Eliana reports to the SEC

Open-market buys and sales

11 trades reported on SEC Form 4, newest first

DateStockTypeValue
Mar 2, 2026NTLA↓ Sell$8K
Jan 5, 2026NTLA↓ Sell$88K
Jul 1, 2025NTLA↓ Sell$10K
Mar 4, 2025NTLA↓ Sell$6K
Jan 3, 2025NTLA↓ Sell$97K
Jul 1, 2024NTLA↓ Sell$9K
Mar 4, 2024NTLA↓ Sell$20K
Jan 3, 2024NTLA↓ Sell$136K
Jul 3, 2023NTLA↓ Sell$15K
Jun 20, 2023NTLA↓ Sell$225K
Jan 4, 2023NTLA↓ Sell$76K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

Other NTLA insiders

Open-market trades in the last 12 months

About Eliana Clark's insider trades

Eliana Clark is EVP, Chief Technical Officer at Intellia Therapeutics (NTLA). Since Jan 4, 2023, Eliana has reported no open-market purchases and 11 sales worth $690K on SEC Form 4. In the last 12 months: 2 sales ($96K).

Their filings also include grants and awards (5 filings), option exercises (1 filing). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every NTLA insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.